ISSUES IN HEPATITIS B VIRUS INFECTION:
CURRENT THERAPIES, PREVENTING RESISTANCE, SPECIAL PATIENT POPULATIONS

Supplement 3 to Volume 76 • May 2009

Supplement Editor
WILLIAM D. CAREY, MD
Cleveland Clinic

This supplement is based on a symposium, “B-SMART: Hepatitis B,” convened at Cleveland Clinic on December 6, 2008. The symposium was part of the “Seventh Annual Liver Update,” a CME activity sponsored by the Cleveland Clinic Center for Continuing Education.

Contents

The prevalence and natural history of hepatitis B in the 21st century ..................... S2
William D. Carey, MD

Risk of hepatocellular carcinoma in hepatitis B and prevention through treatment .......... S6
Morris Sherman, MD, PhD

Understanding cultural barriers in hepatitis B virus infection .............................. S10
Tram T. Tran, MD

Hepatitis B treatment: Current best practices, avoiding resistance .......................... S14
Robert G. Gish, MD

Monotherapy vs multiple-drug therapy: The experts debate ................................. S20
Robert G. Gish, MD, and Pierre M. Gholam, MD

Management of hepatitis B in pregnancy: Weighing the options ............................. S25
Tram T. Tran, MD

Strategies for managing coinfection with hepatitis B virus and HIV .................... S30
Morris Sherman, MD, PhD

Acknowledgment

This supplement was supported by educational grants from Bristol-Myers Squibb Company, whose products include entecavir, and Gilead Sciences, Inc., whose products include adefovir, emtricitabine, and tenofovir. These products are among the therapies discussed in this supplement.

Author and Editor Disclosures

William D. Carey, MD, reported that he has no financial relationships that could be perceived as a potential conflict of interest in the context of his contributions to this supplement.

Pierre M. Gholam, MD, reported that he has received grant/research support from Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals, Inc., Gilead Sciences, Inc., Roche Pharmaceuticals, and Sanofi-Aventis; and consulting fees and honoraria for teaching and speaking from Gilead Sciences, Inc., Onyx Pharmaceuticals, and Vertex Pharmaceuticals.

Robert G. Gish, MD, reported that he has received consulting fees, honoraria for speaker programs, and research grants from Bristol-Myers Squibb Company, Gilead Sciences, Inc., GlaxoSmithKline, Idenix/Novartis, Innogenetics, Merck, Metabasis Therapeutics, Pharmasset, Roche Laboratories, Inc., Schering-Plough, and SciClone Pharmaceuticals.

Morris Sherman, MD, PhD, reported that he has received consulting fees and honoraria for teaching and speaking from Bristol-Myers Squibb Company, Gilead Sciences, Inc., and Roche Laboratories, Inc.

Tram T. Tran, MD, reported that she has no financial relationships that could be perceived as a potential conflict of interest in the context of her contributions to this supplement.